keyword
MENU ▼
Read by QxMD icon Read
search

DPP-4

keyword
https://www.readbyqxmd.com/read/29241903/effect-of-dipeptidyl-peptidase-4-inhibitors-on-heart-failure-a-network-meta-analysis
#1
Wen-Qin Guo, Lang Li, Qiang Su, Wei-Ran Dai, Zi-Liang Ye
BACKGROUND: Previous meta-analyses evaluating the effectiveness of individual dipeptidyl peptidase-4 (DPP-4) inhibitors on the risk of heart failure (HF) were limited because of the small number of trials with direct comparisons between two treatments. METHODS: A Bayesian network meta-analysis was performed to investigate the relationship between DPP-4 inhibitors and the risk of HF in patients with type-2 diabetes mellitus. The primary outcome was the occurrence of HF or hospital admission for HF...
December 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29239764/treatment-choices-for-the-glycaemic-management-of-patients-with-type-2-diabetes-and-chronic-kidney-disease-analysis-of-the-sail-patient-linked-dataset
#2
Thinzar Min, Gareth I Davies, Sam Rice, James Chess, Jeffrey W Stephens
AIMS: Chronic kidney disease (CKD) is common in type 2 diabetes and limits the treatment choices for glycaemic control. Our aim was to examine real-world prescribing for managing hyperglycaemia in the presence of CKD. METHODS: The SAIL (Secure Anonymised Information Linkage) databank was used to examine prescribing during the period from the 1st of January to 30th December 2014. CKD was defined as:- none or mild CKD, eGFR ≥60mL/min/1.73m2; moderate CKD eGFR <60mL/min/1...
November 23, 2017: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/29238240/the-effect-of-dpp-4-inhibitors-on-asthma-control-an-administrative-database-study-to-evaluate-a-potential-pathophysiological-relationship
#3
Gene Colice, David Price, Maria Gerhardsson de Verdier, Karma Rabon-Stith, Christopher Ambrose, Katherine Cappell, Debra E Irwin, Paul Juneau, Anna Vlahiotis
Rationale: DPP-4 may regulate immunological pathways implicated in asthma. Assessing whether DPP-4 inhibitor (DPP-4i) use might affect asthma control is clinically important because DPP-4i use in type 2 diabetes mellitus management (T2DM) is increasing. This study evaluated associations between DPP-4i use and asthma control. Methods: This was a retrospective, observational, matched cohort study using administrative claims in the MarketScan® Commercial Claims and Encounters (Commercial) and Medicare Supplemental and Coordination of Benefits (Medicare Supplemental) databases...
2017: Pragmatic and Observational Research
https://www.readbyqxmd.com/read/29236221/dpp-4-inhibitor-induced-rheumatoid-arthritis-among-diabetics-a-nested-case-control-study
#4
Niranjan Kathe, Anuj Shah, Qayyim Said, Jacob T Painter
INTRODUCTION: The risk of rheumatoid arthritis (RA) associated with dipeptidyl peptidase-4 inhibitor (DPP-4i) use is unclear. This study assesses the RA risk associated with DPP-4i use among a diabetic cohort initiating second-line therapy. METHODS: This was a nested case-control study, using the adult diabetic population starting second-line antidiabetic therapy from IMS LifeLink Plus® database (2006-2015). Cases were those with two or more RA diagnosis, at least one prescription, and 180 days enrollment prior to the event date (earliest of the two: first RA diagnosis, first RA prescription)...
December 13, 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29230196/saxagliptin-induces-%C3%AE-cell-proliferation-through-increasing-stromal-cell-derived-factor-1%C3%AE-in-vivo-and-in-vitro
#5
Chun-Jun Li, Bei Sun, Qian-Hua Fang, Min Ding, Yun-Zhi Xing, Li-Ming Chen, De-Min Yu
Dipeptidyl peptidase-4 inhibitors, such as saxagliptin, have been reported to have beneficial effects on β-cell function, but the specific underlying mechanism remains unclear. Stromal cell-derived factor-1α (SDF-1α), a chemokine produced in multiple organs, has been considered as a crucial regulator in promoting β-cell survival. Here, we speculate that SDF-1α might mediate the effect of saxagliptin on improving β-cell function. After 12-week saxagliptin treatment in high-fat diet/streptozotocin-induced diabetic rats, significant improvement in pancreas insulin secretion capacity evaluated by hyperglycemia clamp and increased β-cell to α-cell areas ratio were observed...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29227575/effect-of-a-single-dose-of-the-dpp-4-inhibitor-sitagliptin-on-%C3%AE-cell-function-and-incretin-hormone-secretion-after-meal-ingestion-in-healthy-volunteers-and-drug-na%C3%A3-ve-well-controlled-type-2-diabetes-subjects
#6
Wathik Alsalim, Olga Göransson, Richard D Carr, Roberto Bizzotto, Andrea Tura, Giovanni Pacini, Andrea Mari, Bo Ahrén
To explore the effects of a single dose of the DPP-4 inhibitor sitagliptin on glucose-standardized insulin secretion and β-cell glucose sensitivity after meal ingestion, twelve healthy- and twelve drug naïve well-controlled type 2 diabetes subjects (T2D; mean HbA1c 43 mmol/mol, 6.2%) received sitagliptin (100mg) or placebo before a meal (525 kcal). β-cell function was measured as the insulin secretory rate at a standardized glucose concentration and the β-cell glucose sensitivity (the slope between glucose and insulin secretory rate)...
December 11, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29225483/active-stromal-cell-derived-factor-1%C3%AE-and-endothelial-progenitor-cells-are-equally-increased-by-alogliptin-in-good-and-poor-diabetes-control
#7
Roberto Negro, Eupremio Luigi Greco, Giacomo Greco
Background: It is postulated that the ability of dipeptidyl peptidase-4 inhibitors (DPP-4-i) to increase circulating endothelial progenitor cells (EPCs) may be at least partly mediated by active stromal cell-derived factor 1α (SDF-1α) (a pivotal mediator of stem cell mobilization from the bone marrow). As other DPP-4-i were demonstrated to increase EPC concentrations, in this study, we sought to investigate the ability of the DPP-4-i alogliptin in modifying EPCs and SDF-1α, in patients with good and poor diabetes control...
2017: Clinical Medicine Insights. Endocrinology and Diabetes
https://www.readbyqxmd.com/read/29223646/exploring-the-effects-of-dpp-4-inhibitors-on-the-kidney-from-the-bench-to-clinical-trials
#8
REVIEW
Giuseppe Coppolino, Christian Leporini, Laura Rivoli, Francesco Ursini, Eugenio Donato di Paola, Valeria Cernaro, Franco Arturi, Davide Bolignano, Emilio Russo, Giovambattista De Sarro, Michele Andreucci
Dipeptidyl-peptidase-4 (DPP-4) inhibitors are a relatively new class of non-insulin glucose-lowering agents, belonging to the incretin family, which are able to improve glycemic control with a favorable safety profile, since they are associated with a low risk of hypoglycemia, no weight gain, and good tolerability in patients with chronic renal failure. Some experimental and clinical studies suggest that these drugs may exert significant pleiotropic effects, in particular on chronic kidney disease (CKD) progression, but data from clinical trials are still controversial...
December 6, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29220092/dose-rectification-of-an-unbalance-between-dpp4-and-glp-1-ameliorates-chronic-stress-related-vascular-aging-and-atherosclerosis
#9
Xian Wu Cheng, Megumi Narisawa, Enze Jin, Chenglin Yu, Wenhu Xu, Limei Piao
Exposure to psychosocial stress is a risk factor for cardiovascular disease, including vascular aging and regeneration. Dipeptidyl peptidase-4 (DPP-4) exerts many physiological and pharmacological functions by regulating its extremely abundant substrates [e.g., glucagon-like peptide-1 (GLP-1), stromal cell-derived factor-1α/ C-X-C chemokine receptor type-4, etc.]. Over the past decade, emerging data revealed unexpected roles for DPP-4 and GLP-1 in intracellular signaling, oxidative stress production, lipid metabolism, cell apoptosis, immune activation, insulin resistance, and inflammation...
December 8, 2017: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/29213240/dipeptidyl-peptidase-4-inhibitors-use-and-relative-risk-of-ischemic-cerebrovascular-disease-in-type-2-diabetic-patients-in-a-case-control-study
#10
Shih-Wei Lai, Kuan-Fu Liao, Cheng-Li Lin, Hsien-Feng Lin
Background and Objectives: Limited research focuses on the risk of ischemic cerebrovascular disease associated with use of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) in patients with type 2 diabetes mellitus in Taiwan. This study aimed to investigate the association between DPP-4 inhibitors use and the first episode of ischemic cerebrovascular disease. Methods: We designed a case-control study using the database of the Taiwan National Health Insurance Program. There were 1999 type 2 diabetic subjects aged 20-84 years with the first episode of ischemic cerebrovascular disease from 2000 to 2013 as the cases, and 7996 sex- and age-matched, randomly selected type 2 diabetic subjects aged 20-84 years without any type of cerebrovascular diseases as the matched controls...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29208515/effectiveness-of-sitagliptin-in-a-patient-with-late-dumping-syndrome-after-total-gastrectomy
#11
Kotomi Kurihara, Anna Tamai, Yoko Yoshida, Yosuke Yakushiji, Hiroki Ueno, Mariko Fukumoto, Masayuki Hosoi
An 83-year-old man developed hypoglycemia after undergoing total gastrectomy for gastric cancer in 200X-4. The patient was admitted to our hospital in May 200X and placed on continuous glucose monitoring (CGM). Glycemic excursions were examined while on 3-meal/day (1700kcal) and 6-meal/day (1800kcal) diets. Oxyhyperglycemia followed about 2h later by a sudden drop in glucose levels was seen with both regimens. These findings were consistent with late dumping syndrome. CGM was continued, oral miglitol at 150mg/day or sitagliptin at 50mg/day was started, and glycemic excursions were compared...
November 29, 2017: Diabetes & Metabolic Syndrome
https://www.readbyqxmd.com/read/29206336/claims-based-studies-of-oral-glucose-lowering-medications-can-achieve-balance-in-critical-clinical-parameters-only-observed-in-electronic-health-records
#12
E Patorno, C Gopalakrishnan, J M Franklin, K G Brodovicz, E Masso-Gonzalez, D B Bartels, J Liu, S Schneeweiss
BACKGROUND: Healthcare claims databases can provide information on the effects of type 2 diabetes (T2DM) medications as used in routine care, but often do not contain data on important clinical characteristics, which may be captured in electronic health records (EHR). OBJECTIVES: To evaluate the extent to which balance in unmeasured patient characteristics was achieved in claims data, by comparing against more detailed information from linked EHR data. METHODS: Within a large US commercial insurance database and using a cohort design, we identified T2DM patients initiating linagliptin or a comparator agent within class (i...
December 5, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29205013/study-on-regulation-of-adipokines-on-body-fat-distribution-and-its-correlation-with-metabolic-syndrome-in-type-2-diabetes-mellitus
#13
Xiaoxi Liu, Xiaojuan Li, Changhui Li, Chengjun Gong, Songyan Liu, Yan Shi
BACKGROUND: This paper aims to investigate the regulating role of adipokine expression level in body fat distribution of patients with type 2 diabetes mellitus (T2MD) as well as its correlation with metabolic syndrome (MS). METHODS: 140 patients with T2MD admitted in the Endocrinology Department of the First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine from January 2017 to July 2017 were selected; their body height and weight were measured to calculate body mass index (BMI); patients with a BMI ≤23...
December 4, 2017: Minerva Endocrinologica
https://www.readbyqxmd.com/read/29203362/hla-dqb1-03-01-as-a-biomarker-for-genetic-susceptibility-to-bullous-pemphigoid-induced-by-dpp-4-inhibitors
#14
Hideyuki Ujiie, Ken Muramatsu, Taisei Mushiroda, Takeshi Ozeki, Hideaki Miyoshi, Hiroaki Iwata, Akinobu Nakamura, Hiroshi Nomoto, Kyu Yong Cho, Norihiro Sato, Machiko Nishimura, Takamasa Ito, Kentaro Izumi, Wataru Nishie, Hiroshi Shimizu
No abstract text is available yet for this article.
December 1, 2017: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29195509/dpp-4-inhibition-with-linagliptin-ameliorates-the-progression-of-premature-aging-in-klotho-mice
#15
Yu Hasegawa, Kenyu Hayashi, Yushin Takemoto, Cao Cheng, Koki Takane, Bowen Lin, Yoshihiro Komohara, Shokei Kim-Mitsuyama
BACKGROUND: The potential of anti-aging effect of DPP-4 inhibitors is unknown. This study was performed to determine whether linagliptin, a DPP-4 inhibitor, could protect against premature aging in klotho-/- mice. METHODS: Klotho-/- mice exhibit multiple phenotypes resembling human premature aging, including extremely shortened life span, cognitive impairment, hippocampal neurodegeneration, hair loss, muscle atrophy, hypoglycemia, etc. To investigate the effect of linagliptin on these aging-related phenotypes, male klotho-/- mice were divided into two groups: (1) control group fed the standard diet, and (2) linagliptin group fed the standard diet containing linagliptin...
December 1, 2017: Cardiovascular Diabetology
https://www.readbyqxmd.com/read/29187821/renoprotective-effect-of-dipeptidyl-peptidase-4-inhibitors-in-patients-with-type-2-diabetes-mellitus
#16
Hiroki Esaki, Tomoya Tachi, Chitoshi Goto, Ikuto Sugita, Yuta Kanematsu, Aki Yoshida, Kosuke Saito, Yoshihiro Noguchi, Yuki Ohno, Satoshi Aoyama, Masahiro Yasuda, Takashi Mizui, Masumi Yamamura, Hitomi Teramachi
Diabetic nephropathy is one of three major complications of diabetes mellitus, often leading to chronic renal failure requiring dialysis. Recently developed dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit renoprotective effects in addition to antihyperglycemic effects. In this study, we retrospectively investigated temporal changes in the renal function index of patients with type 2 diabetes mellitus (DM) and examined the influence of DPP-4 inhibitors on renal function. Patients with type 2 DM (>18 years old) prescribed hypoglycemic agents at Gifu Municipal Hospital for ≥3 months between March 2010 and April 2014 were included in the study...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/29175506/cd26-expression-is-down-regulated-on-cd8-t-cells-in-patients-with-hashimoto-s-thyroiditis
#17
Yalei Liu, Yuan Li, Yan Gong, Nan Yu, Yang Zhang, Ran You, Chenxue Qu, Guizhi Lu, Youyuan Huang, Ying Gao, Yanming Gao, Xiaohui Guo
The immune mechanism underlying Hashimoto's thyroiditis (HT) remains unclear. CD26, also known as dipeptidyl peptidase 4 (DPP-4), is a multifunctional molecule involved in the pathophysiology of autoimmune diseases. This study aimed to investigate the role of CD26 in the pathogenesis of HT. Peripheral blood was drawn from 20 healthy controls and 31 HT patients (19 mild HT patients and 12 severe HT patients). Plasma sCD26 concentrations were measured by ELISA, and sCD26 enzymatic activity was assessed using a luciferase-based assay...
November 23, 2017: International Immunopharmacology
https://www.readbyqxmd.com/read/29172255/relationship-between-deterioration-of-hba1c-lowering-effects-in-dpp-4-inhibitor-monotherapy-and-dietary-habits-retrospective-analysis-of-japanese-individuals-with-type-2-diabetes
#18
Hitoshi Kuwata, Saki Okamoto, Yusuke Seino, Kenta Murotani, Hisato Tatsuoka, Ryota Usui, Yoshiyuki Hamamoto, Takeshi Kurose, Yutaka Seino, Daisuke Yabe
This study was designed to assess possible relationships between deterioration of the HbA1c-lowering effects in dipeptidyl peptidase-4 inhibitor (DPP4i) monotherapy and macronutrient intake among individuals with type 2 diabetes (T2D). T2D individuals who began and continued DPP4i monotherapy without any prescription change for 1 year were retrospectively stratified into two groups: patients who maintained their HbA1c levels during the 0.5- to 1-year period after DPP4i initiation [Group A, ΔHbA1c (1-0.5 year)<0...
November 24, 2017: Journal of Diabetes Investigation
https://www.readbyqxmd.com/read/29171139/randomized-double-blind-placebo-controlled-dose-finding-study-of-the-dipeptidyl-peptidase-4-inhibitor-linagliptin-in-pediatric-patients-with-type-2-diabetes
#19
William V Tamborlane, Lori Mb Laffel, Jacques Weill, Maud Gordat, Dietmar Neubacher, Silke Retlich, Willem Hettema, Cornelia E Hoesl, Stefan Kaspers, Jan Marquard
OBJECTIVE: To identify the dose of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin in pediatric patients with type 2 diabetes (T2D). METHODS: Double-blind, randomized, controlled parallel group study comparing linagliptin 1 and 5 mg once daily, with placebo in 39 patients with T2D aged 10 to below 18 years. The primary efficacy endpoint was the change from baseline in glycated hemoglobin (HbA1c) after 12 weeks of treatment. The key pharmacodynamic endpoint was DPP-4 inhibition during steady-state...
November 24, 2017: Pediatric Diabetes
https://www.readbyqxmd.com/read/29169334/prevalence-and-treatment-of-diabetes-mellitus-and-hypertension-among-older-adults-with-intellectual-disability-in-comparison-with-the-general-population
#20
Anna Axmon, Gerd Ahlström, Peter Höglund
BACKGROUND: Diabetes mellitus and hypertension are risk factors for cardiovascular disease, which is the most common cause of death in the world. People with intellectual disability (ID) have been reported to have high rates of both these disorders. The aim of this study was to describe and compare prevalence ratios of diabetes mellitus and hypertension between older adults with ID and their age peers in the general population, and to describe and compare treatment patterns in these two groups...
November 23, 2017: BMC Geriatrics
keyword
keyword
58365
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"